Quantcast

North America

Gilead Sciences’ top person, Daniel O’Day on 5-day treatment course with remdesivir for $2,340 per patient

Remdevisir has become a popular word these days, along with Covid-19, Coronavirus, the city of Wuhan, and for a good reason. The headline in all the news, the pricing of remdevisir, has been flooding the internet, and pretty much the TV.

Posted in news, North America | Tagged , , , | Leave a comment

Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor

Posted in news, North America | Tagged , , , | Leave a comment

Health Canada lets certain COVID-19 patients to take NuvOx Pharma’s Oxygen therapeutic in phase II clinical trial (edit)

NuvOx Pharma ensured the continuation of Phase 2 clinical trial of its NanO2 in Covid-19 patients with acute hypoxic respiratory failure, as it got No Objection Letter from Health Canada.

Posted in news, North America | Tagged , , | Leave a comment

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

Arya and Immatics’s previouslly announced business combination into combined company called Immatics N.V., has been approved by both companies’ shareholders,

Posted in news, North America | Tagged | Leave a comment

Seattle Genetics’s testing tisotumab vedotin in recurrent or metastatic cervical cancer (updated)

Seattle Genetics’ results from the phase 2 of trial testing tisotumab vedotin  to treat patients with relapsed or progressed metastatic cervical cancer, showed clinically meaningful and durable objective responses with a manageable safety profile.

Posted in news, North America | Tagged , , | Leave a comment

Rocket Pharmaceuticals gets FDA clearance for its gene therapy for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-L401, its, lentiviral vector (LVV)-based gene therapy for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder.

Posted in news, North America | Tagged , | Leave a comment

NanoImaging Services Expands with New East Coast Facility

NanoImaging Services (NIS) said on Thursday that it is opening a new facility in Boston to support its growing customer base requiring cryoEM for drug discovery and vaccine development applications. COVID-19 projects are receiving prioritization.

Posted in news, North America | Tagged | Leave a comment

Piramal Pharma buys solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.

Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to customary preclosing conditions.

Posted in news, North America | Leave a comment

UPDATE — Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials

IND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease SOUTH SAN FRANCISCO, Calif., June 19, 2020

Posted in news, North America | Tagged | Leave a comment

Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections

TORONTO, June 19, 2020 (GLOBE NEWSWIRE) — New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence

Posted in news, North America | Tagged , | Leave a comment